The 2023-2028 Outlook for Diabetic Foot Ulcer Therapeutics in India

This study covers the latent demand outlook for diabetic foot ulcer therapeutics across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in que...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Diabetic Foods in India

This study covers the latent demand outlook for diabetic foods across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Diabetic Confectionery Foods in India

This study covers the latent demand outlook for diabetic confectionery foods across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in questio...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Diabetic Care Devices in India

This study covers the latent demand outlook for diabetic care devices across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the ...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Diabetes Treatments in India

This study covers the latent demand outlook for diabetes treatments across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the pe...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Diabetes Treatment Devices in India

This study covers the latent demand outlook for diabetes treatment devices across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question,...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Diabetes Therapeutics and Diagnostics in India

This study covers the latent demand outlook for diabetes therapeutics and diagnostics across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city i...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Diabetes Therapeutics in India

This study covers the latent demand outlook for diabetes therapeutics across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the ...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Diabetes Monitoring, Treatment, and Drug Delivery Products in India

This study covers the latent demand outlook for diabetes monitoring, treatment, and drug delivery products across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in I...

9/14/2022 | India Outlook 2023

The 2023-2028 Outlook for Diabetes Monitoring Devices in India

This study covers the latent demand outlook for diabetes monitoring devices across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question...

9/14/2022 | India Outlook 2023

This study covers the latent demand outlook for diabetic foot ulcer therapeutics across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for diabetic foot ulcer therapeutics. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of diabetic foot ulcer therapeutics as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include 3M Company, Acelity L.P., B. Braun Melsungen, Derma Sciences, Innocoll Holdings, Organogenesis, Osiris, Sigvaris, and Smith & Nephew. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for diabetic foods across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for diabetic foods. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of diabetic foods as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Anhui Elite Industrial Company, Breisgaumilch GmbH, Britannia Industries, Cadbury, Chapman's, Dabur, Danone, David Chapman’s Ice Cream, Fifty 50 Foods, H. J. Heinz Company, Herboveda India, ITC, Kellogg Company, Mars, Mondelēz International, Mondelez United Kingdom, Nestec, Nestle, Nestlé, Newtrition Plus Health, PepsiCo, Saputo, SoSweet, TFI Holdings, The Coca Cola, Unilever, Wellness Pvt, Ltd., and Zen Health Japan. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for diabetic confectionery foods across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for diabetic confectionery foods. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of diabetic confectionery foods as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Danone, ITC, Nestec, The Hershey Company, and Unilever. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for diabetic care devices across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for diabetic care devices. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of diabetic care devices as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Bayer, Eli Lilly and Company, LifeScan, Medtronic, Novo Nordisk, and Roche. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for diabetes treatments across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for diabetes treatments. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of diabetes treatments as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott Laboratories, Amylin Pharmaceuticals, Arkray, Ascensia Diabetes Care Holdings, AstraZeneca, Bayer, Becton, Boehringer Ingelheim International, Dexcom, Dickinson, Eli Lilly, GlaxoSmithKline, Home Diagnostics, Inc., Johnson & Johnson, Medtronic, Merck & Company, NextCell Pharma AB, Novartis, Novo Nordisk, Roche Products, Ltd., Sanofi-Deutschland, Takeda Pharmaceutical Company, Teva Pharmaceuticals Industries, and Ypsomed Holding. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for diabetes treatment devices across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for diabetes treatment devices. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of diabetes treatment devices as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott, B. Braun Melsungen, BD, F. Hoffmann-La Roche, Medtronic, PLC, Novo Nordisk, Sanofi, and Tandem Diabetes Care. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for diabetes therapeutics and diagnostics across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for diabetes therapeutics and diagnostics. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of diabetes therapeutics and diagnostics as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbot Laboratories, Bayer, Becton Dickson, Merck, Sanofi, and Takeda. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for diabetes therapeutics across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for diabetes therapeutics. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of diabetes therapeutics as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Merck & Company, Novartis, Novo Nordisk, Sanofi, and Takeda Pharmaceutical Company. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for diabetes monitoring, treatment, and drug delivery products across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for diabetes monitoring, treatment, and drug delivery products. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of diabetes monitoring, treatment, and drug delivery products as including all commonly understood products falling within this broad category, such as professional and personal blood glucose meters and test strips lancet and lancing devices continuous glucose monitoring systems and sensors insulin pumps long and rapid acting, and premixed modern insulin insulin syringes and prefilled, pen cartridge and needle, and reusable insulin pens, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Eli Lilly and Company, F. Hoffmann-La Roche, LifeScan, Medtronic, PLC, Novo Nordisk, and Sanofi. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

This study covers the latent demand outlook for diabetes monitoring devices across the states, union territories, and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across over 4,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state, union territory, and city, latent demand estimates are created for diabetes monitoring devices. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of diabetes monitoring devices as including all commonly understood products falling within this broad category, such as devices used to measure blood glucose levels, such as blood glucose meters and testing strips, glucose and ketone urine test strips, lancets and lancing devices, and non-invasive measuring devices, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott Laboratories, Ascensia Diabetes Care Holdings, Bayer, DiaMonTech, F. Hoffmann-La Roche, Johnson and Johnson, Lifespan, Roche Diagnostics, Sanofi, and Terumo Medical. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

9/14/2022

LATEST REPORTS

PRESS RELEASES

Use Code

SDMR20

Purchase any report

AVAIL FLAT DISCOUNT